Literature DB >> 17030273

Extent of surgical resection for esophageal and gastroesophageal junction adenocarcinomas.

Bart C Vrouenraets1, J Jan B van Lanschot.   

Abstract

The early-stage lymphatic dissemination in esophageal cancer poses challenges for adequate surgical treatment. The role of extensive lymph node dissections remains a matter of debate. Results of the only available large randomized controlled trial suggest that fit patients who have esophageal cancer are treated best by a transthoracic esophagectomy with extended en bloc (two-field) lymphadenectomy. For less fit patients or patients who have junctional or cardiac tumors, transhiatal esophageal resection could suffice. In patients who have truly "early" adenocarcinoma (ie, with high-grade dysplasia or intramucosal carcinoma) endoscopic resectional or ablative treatments may be suitable. When the tumor invades the submucosal layer, the high risk for lymph node involvement and tumor recurrence probably necessitates more extensive treatment schedules for definitive cure.

Entities:  

Mesh:

Year:  2006        PMID: 17030273     DOI: 10.1016/j.soc.2006.07.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  3 in total

1.  The esophagogastric junctional adenocarcinoma an increasing disease.

Authors:  Monica Pastina; Cecilia Menna; Claudio Andreetti; Mohsen Ibrahim
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Postoperative complications do not affect long-term outcome in esophageal cancer patients.

Authors:  Kirsten Lindner; Mathias Fritz; Christina Haane; Norbert Senninger; Daniel Palmes; Richard Hummel
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

3.  Treatment of postoperative esophagorespiratory fistulas with dual self-expanding metal stents.

Authors:  Thorhallur Agustsson; Magnus Nilsson; Gert Henriksson; Urban Arnelo; Jan E Juto; Lars Lundell
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.